Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab
Research payments
$145,266
Through program year 2020, $145,266 in research payments was reported against Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab, across 29 payments, paid by Sanofi US Services Inc..
- Paid by
- Sanofi US Services Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | Research | $145,266 | 29 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jonathan Bernstein Cincinnati, OH Named on 7 payments
- Gary Gross Dallas, TX Named on 6 payments
- Jeffrey Tillinghast Saint Louis, MO Named on 6 payments
- Hugh Windom Sarasota, FL Named on 3 payments
- Roopen Patel Charlotte, NC Named on 2 payments
- John Niven Miami Beach, FL Named on 2 payments
- Lisa Beck Rochester, NY Named on 1 payment
- Erika Gonzalez San Antonio, TX Named on 1 payment
- Brad Goodman Savannah, GA Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.